Elastrin Therapeutics Strengthens its Leadership Team by App

(0)
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer. Pedro will be responsible for the clinical and regulatory strategy, planning, and execution of the company's clinical development plans.
"We are delighted to bring someone with Pedro's impressive expertise and experience on board during this exciting time for Elastrin," said Dr. Matthias Breugelmans, CEO at Elastrin Therapeutics. "His deep knowledge of cardiovascular research and medicine from both an industry and academic perspective is a strong addition to Elastrin preparing for clinical trials. His experience developing early-stage programs into commercial products will be instrumental developing our novel therapies to reverse cardiovascular disease during the next years" declared Prof. Naren Vyavahare, Chief Scientific Officer at Elastrin Therapeutics.

Related Keywords

Grunenthal , Nordrhein Westfalen , Germany , Kostenloser Wertpapierhandel , Patrick Burgermeister , Pedrom Quintana Diez , Naren Vyavahare , Matthias Breugelmans , Dagmars Metzger , Revel Pharmaceuticals , Clemson University , Healthy Group , Sensory Sciences , Elastrin Therapeutics Inc , Chief Medical , Chief Scientific Officer , Chief Medical Officer , Elastrin Therapeutics , Board Member , South Carolina Based , Forever Healthy Group , Undoing Aging , Elastrin , Herapeutics , Trengthens , Leadership , Team , Appointing , Pedro , Quintana , Kiez , Chief , Medical , Officer , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , ஜெர்மனி , மகிழ்ச்சி மருந்துகள் , கிளெம்சன் பல்கலைக்கழகம் , ஆரோக்கியமான குழு , உணர்ச்சி அறிவியல் , தலைமை மருத்துவ , தலைமை அறிவியல் அதிகாரி , தலைமை மருத்துவ அதிகாரி , பலகை உறுப்பினர் , தெற்கு கரோலினா அடிப்படையிலானது , என்றென்றும் ஆரோக்கியமான குழு , எஅம் ,